GLP-1 receptor agonists like semaglutide and liraglutide operate as chronometabolic modulators, influencing circadian biology through bidirectional interactions with central and peripheral clock networks. The drugs affect hypothalamic and hepatic circadian regulation while GLP-1 secretion from intestinal L-cells follows circadian patterns controlled by core clock genes, making incretin rhythms vulnerable to shift work and sleep disruption. This mechanistic understanding represents a paradigm shift from viewing GLP-1 drugs as simple weight-loss medications to recognizing them as integrative metabolic-circadian therapeutics. The clinical implications are profound for precision medicine approaches, particularly given emerging evidence linking these agents to improved sleep apnea outcomes. However, the field remains nascent with limited human chronotherapy data. The vulnerability of incretin rhythms to circadian misalignment suggests that timing of GLP-1 administration could significantly impact efficacy, opening new avenues for personalized dosing strategies. This chronometabolic framework could revolutionize how we approach not just diabetes and obesity, but sleep disorders and shift work-related metabolic dysfunction.